Trial of your own engineered T cells for ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 1 study tests whether giving your own immune cells—engineered to target the FSH receptor—can control recurrent ovarian-related cancers. It’s mainly looking at safety and early signs of activity for patients whose cancer has not responded well to standard platinum chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 18 or older and can give informed consent.
- Your cancer diagnosis is confirmed ovarian, primary peritoneal, or fallopian tube cancer (or certain related tumor types), and it is serous/endometrioid/clear cell/mucinous/mixed/undifferentiated (or allowed special subtypes like borderline/sex cord-stromal).
- Your cancer has measurable disease or detectable (non-measurable) disease, and you agree to provide a tumor sample for extra lab testing.
- You’ve had treatment with platinum chemotherapy before, and your cancer either keeps growing during it (platinum-refractory) or returns within 6 months after it (platinum-resistant).
- You’re well enough to travel through treatment (ECOG 2 or better or Karnofsky ≥60%) and expected to live at least 3 months; your organ labs (bone marrow, kidneys, liver) are within allowed ranges.
- For safety, you must avoid certain recent treatments: no chemotherapy/biologic/immunotherapy in the 3 weeks before the T-cell infusion, no immune “checkpoint” drugs in the 3 months before, and you must stop hormone therapy (if you’re on it) at least 1 week before the T-cell infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach using your own immune cells (tumor-infiltrating lymphocytes) that have been modified to work better, followed by a combination of oral chemo and immunotherapy. It's for people with ovarian cancer that has come back after standard treatment.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This early-phase trial tests a lab-made immune cell treatment designed to recognize ovarian cancer and attack it. It may help people with high-risk ovarian cancer who still need effective options.
This trial tests a new type of immune therapy called CAR T-cells (SCT-001) for ovarian cancer that has returned or isn't responding to standard treatments. The cells are engineered to find and attack cancer cells that have a specific marker (TAG-72) on their surface.
This laboratory study uses ovarian cancer fluid collected during surgery to test possible new treatments on cancer and immune cells. It may help researchers find better treatment options in ovarian cancer.
This study tests a personalized cancer therapy designed just for you and your tumor. It is for people with newly diagnosed advanced ovarian cancer who can wait a short time before starting treatment and plan to have surgery after 2 cycles of chemotherapy.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.